Sartorius, Sartorius Stedim Biotech shares jump after results beat

Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Finance

Posted By Global Banking and Finance Review

Posted on January 28, 2025

Sartorius, Sartorius Stedim Biotech shares jump after results beat

(Reuters) - Shares in Sartorius jumped 15.6% on Tuesday after the Franco-German lab supplies maker's preliminary annual results beat expectations and despite a cautious outlook for 2025.

"Business development in the second half of the year, and especially in the final quarter, confirms our estimate that the temporary weakness in demand is coming to an end and that the industry will gradually return to its robust, structurally underlying growth trend," CEO Joachim Kreuzburg said in a statement.

The company reported its annual underlying earnings before interest, tax, depreciation and amortisation (EBITDA) of 945 million euros ($985.54 million), topping a Vara consensus estimate of 932.7 million.

Fourth-quarter orders for its key Bioprocess Solutions division (BPS) rose 23.1% to 856.7 million euros, representing a 22% beat to J.P. Morgan estimates.

Underlying EBITDA and order intake beat should support Sartorius shares and those of its French subsidiary Sartorius Stedim Biotech on Tuesday, J.P.Morgan said in a note to clients.

Shares in Sartorius Stedim Biotech were up 13.9% in morning trade.

Both shares are on track for their best day since October.

Shares in Sartorius peer Merck KGaA were up 5.5%.

For 2025, Sartorius expects continuous demand recovery and growth in the life science market, albeit at a rate below its long-term average.

The company anticipates growth in underlying EBITDA will outpace sales revenue, citing expected volume development and positive product mix effects.

The company plans to publish a quantitative forecast after the first quarter of 2025, IT said.

($1 = 0.9589 euros)

(Reporting by Amir Orusov and Anastasiia Kozlova)

Recommended for you